Johnson & Johnson Innovation – JJDC
CVC
Active
New Brunswick, United States
90
48M
66
1.76
16
0.27
6
- Areas of investment
Summary
The leading representative office of defined VC is situated in the Cambridge. The company was established in North America in United States. Johnson & Johnson Innovation u2013 JJDC appeared to be a CVC structure as part of the corporation.
The increased amount of exits for fund were in 2018. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. This Johnson & Johnson Innovation u2013 JJDC works on 23 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Johnson & Johnson Innovation u2013 JJDC, startups are often financed by Wildcat Capital Management, Johnson & Johnson Development Corporation, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are Wildcat Capital Management, Whittier Ventures, VSP Global. In the next rounds fund is usually obtained by dRx Capital, Lux Capital, Lightstone Ventures.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Memebox, Fusion Pharmaceuticals, X-Vax Technology We can highlight the next thriving fund investment areas, such as Pharmaceutical, Therapeutics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.
Investor highlights
- Industry focus
- Stage focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 90
- Lead investments
- 16
- Exits
- 6
- Rounds per year
- 1.76
- Follow on index
- 0.27
- Investments by industry
- Health Care (56)
- Biotechnology (53)
- Medical (42)
- Medical Device (27)
- Therapeutics (23) Show 38 more
- Investments by region
-
- United States (62)
- United Kingdom (6)
- Israel (8)
- Canada (1)
- Switzerland (1) Show 7 more
- Peak activity year
- 2020
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 37M
- Group Appearance index
- 0.91
- Avg. company exit year
- 4
- Avg. multiplicator
- 2.98
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Bright Peak Therapeutics | 11 Jun 2024 | Biotechnology, Therapeutics | Late Stage Venture | 90M | Switzerland, Basel-City, Basel |
ROME Therapeutics | 12 Sep 2023 | Biotechnology, Health Care, Pharmaceutical | Early Stage Venture | 72M | United States, Massachusetts, Cambridge |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.